Gilead and Roche Favor Early-Stage Asset Deals Over Full Buyouts
A biotech deal roundup says large drugmakers favored targeted asset purchases and licensing deals for early-stage candidates this week, rather than full-company acquisitions.
Related stories
Pricol Promoters to Sell 38.51% Stake in Autotech Unit to Warburg Pincus
Pricol said its board approved the sale of promoters’ entire 38.51% shareholding in Pricol Autotech Limited to Warburg Pincus.
M impact | MNA | Nov 14, 2026, 02:29 AM UTC
High Arctic Energy Services Agrees to Go-Private Sale to Newport Capital
High Arctic Energy Services entered into a definitive acquisition agreement and announced its intent to make a cash distribution to shareholders.
M impact | MNA | Nov 14, 2026, 01:01 AM UTC
Gilead Expects HIV Revenue to Grow About 12% in 2026
Gilead expects HIV revenue to grow about 12% in fiscal 2026.
M impact | EARNINGS | Nov 14, 2026, 12:44 AM UTC
Hall Chadwick Acquisition Sets Shareholder Vote on REEcycle Merger
Hall Chadwick Acquisition announced a shareholder meeting to vote on its merger with REEcycle.
M impact | MNA | Nov 13, 2026, 09:49 PM UTC
Surgery Partners Raises HealthSpan Merger Price to $25 per Share
Surgery Partners raised its merger price for HealthSpan to $25 per share after a competing bid.
M impact | MNA | Nov 13, 2026, 05:53 PM UTC
GCI Completes Quintillion Acquisition to Consolidate Alaska Fibre Networks
GCI completed its acquisition of Quintillion, consolidating Alaska fibre networks.
M impact | MNA | Nov 13, 2026, 05:53 PM UTC